Search results for "Cancérologie"
showing 5 items of 5 documents
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
2016
Background:This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC).Methods:Patients received 800-mg intravenous necitumumab (day 1; 2-week cycles), followed by oxaliplatin 85 mg m -2, folinic acid 400 mg m -2, and 5-fluorouracil (400 mg m -2 bolus then 2400 mg m -2 over 46 h). Radiographic evaluation was performed every 8 weeks until progression. Primary endpoint was objective response rate.Results:Forty-four patients were enrolled and treated. Objective response rate was 63.6% (95% confidence interval 47.8-77.6); complete response was observed in …
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
2020
This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-mutated cutaneous melanoma were randomized 2:1 to pimasertib (60 mg
Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…
2013
PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …
Identification of non-canonical NLRP3 functions in Th17 cells - Therapeutic interest to promote antitumor immune response
2021
Since decades, cancers have become a major public health issue, occupying the first premature mortality cause in France. One of the hallmarks of cancer cells is their ability to escape the immune system surveillance, notably through setting up an immunosuppressive environment within the tumor. The NLRP3 protein is largely studied in the inflammasome context, which is assembled in order to promote inflammation through IL-1β secretion. However, this protein also functions as a transcription factor in CD4+ T cells. Indeed, in Th2 cells, NLRP3 cooperate together with IRF4, to form a complex that is able to activate the transcription of Il4, Il5 and Il13, which are necessary for the function of …
Rapport annuel 2006-2007 de l'Observatoire national de la démographie des professions de santé.
2008
Ce troisième rapport de l'Observatoire national de la démographie des professions de santé comporte une synthèse générale assortie de préconisations et de quatre tomes thématiques : la médecine générale (tome 1), les internes en médecine (tome 2), la profession de chirurgien dentiste et les métiers de la périnatalité (tome 3), les métiers de la cancérologie (tome 4).